Resources
50 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 12/15/2021
More than twenty percent of adults—or 1 in 5—experience a behavioral health disorder every year in the United States. Behavioral health disorders can be challenging to identify, screen for and treat, especially in rural communities and the supply of behavioral health providers often cannot meet the demand for services. This webinar highlighted state policy options to increase access to rural behavioral health providers, including leveraging telebehavioral health, considering licensing policies and compacts, utilizing emerging health professionals to address workforce gaps, and examining scope of practice policies for behavioral health professionals.
Posted 2/9/2022 (updated 3/26/2024)
Summary of innovation abstracts that were presented at the National Academy of Medicine’s recent Stigma of Addiction Summit.
Posted 3/3/2022 (updated 3/26/2024)
Drug overdose is a nationwide epidemic that claimed the lives of over 100,000 people in the United States in the past year. Opioids, either alone or in combination with other drugs or alcohol, were responsible for approximately 70 percent of these deaths. Many of those 70,000 people would be alive today if they had been administered the opioid antagonist naloxone and, where needed, other emergency care.
Posted 8/10/2022 (updated 3/27/2024)
Researchers looked at what happens in rural and urban emergency departments (EDs) when peer-based services are used for patients arriving with opioid use disorder (OUD). The study aimed to find gaps in knowledge for rural EDs and found five key differences from urban counterparts that presented a challenge. Among these was difficulty identifying community partners.
Posted 10/12/2022 (updated 3/27/2024)
From rural McDowell County to urban Forsyth, emergency services departments statewide say the labor shortage paired with high call volumes might mean it’ll take longer for an ambulance to arrive at your door.
Patients Treated With Buprenorphine in Emergency Departments More Likely To Continue After Discharge
Posted 4/11/2023 (updated 3/27/2024)
In this cohort study of 17,428 Medicaid-enrolled adults with an emergency department encounter for opioid use disorder, the buprenorphine treatment Opioid Hospital Quality Improvement Program (O-HQIP) pathway was associated with significantly increased prescription fills for buprenorphine within 30 days of discharge.
Posted 10/25/2022 (updated 3/27/2024)
Hepatitis C: State of Medicaid Access is a collaboration between the Center for Health Law and Policy Innovation of Harvard
Law School (CHLPI) and the National Viral Hepatitis Roundtable (NVHR). The project evaluates hepatitis C (HCV)
treatment restriction policies across state Medicaid programs, including all 50 states, the District of Columbia, and Puerto
Rico (referred to in this report as “states”). The goal of this project is to encourage states and empower advocates to work
toward improved access to curative HCV treatment across all Medicaid programs, in order to ensure that every Medicaid
enrollee who can benefit from this treatment is able to access it.
Posted 4/14/2023 (updated 3/27/2024)
Researchers evaluate The Kentucky Access to Recovery Program (KATR), which provides services to individuals recovering from opioid use in several counties in Eastern Kentucky, and conclude KATR demonstrates a potentially effective strategy for increasing health-related social services in rural areas.
Posted 11/15/2022 (updated 3/27/2024)
In this decision analytical model study evaluating the distribution of 10 000 additional naloxone kits annually in Rhode Island, the strategy focusing on distribution of naloxone according to geographic need to people who inject drugs resulted in the best outcomes at the lowest cost, averting an estimated 25.3% of opioid overdose deaths at an incremental cost of $27 312 per opioid overdose death averted
Posted 6/8/2023 (updated 3/27/2024)
Buprenorphine is a medication approved by the U.S. Food and Drug Administration to treat opioid use disorder (OUD) with a relatively low rate of triggering precipitated withdrawal in patients. Increased precipitated withdrawal rates have become a concern for practitioners in emergency departments when treating with buprenorphine with the prevalence of fentanyl in the drug supply.